

INDGN/SE/2024-25/23

August 1, 2024

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
---	---

Dear Sir / Madam,

Sub: Press Release regarding financial results for the quarter ended June 30, 2024

We wish to inform you that the Company has made a press release dated August 1, 2024, announcing the financial results for the quarter ended June 30, 2024 as approved by the Board of Directors at its meeting on August 1, 2024 (VIA AUDIO/VIDEO MODE).

A copy of the Press Release is attached for your records.

Please acknowledge the receipt.

Thanking you,

Yours Sincerely,

For Indegene Limited
(Formerly known as Indegene Private Limited)

Srishti Ramesh Kaushik
Company Secretary and Compliance officer



Indegene Limited (Formerly Indegene Private Limited),
Third Floor, Aspen G-4 Block, Manyata Embassy
Business Park (SEZ), Outer Ring Road, Nagawara,
Bengaluru- 560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: U73100KA1998PLC102040

Press Release

Indegene reports robust profit growth for Q1FY25

Bengaluru, India, 01 August 2024: Indegene Limited (BSE: 544172, NSE: INDGN), a leading digital-first commercialization services company, announced financial results for the quarter ended June 30, 2024.

- Achieved revenue of INR 6,765 million in Q1FY25 with growth of 11.4% vs Q1FY24
- Robust EBITDA growth of 14.5% in Q1FY25 vs Q1FY24
- Became a zero-debt company

Sl. No.	Particulars	Quarter ended		
		June 30, 2024	Mar 31, 2024	June 30, 2023
1.	Revenue from operations	6,765	6,730	6,075
2.	Revenue from operations ⁽¹⁾ (\$ Mn)	81.1	81.1	73.9
3.	YoY revenue growth from operations ⁽²⁾ (%)	11.4%	6.5%	16.6%
4.	EBITDA ⁽³⁾	1,328	1,474	1,160
5.	EBITDA margin (%)	19.6%	21.9%	19.1%
6.	Profit after tax	877	948	684
7.	Profit margin (%)	13.0%	14.1%	11.3%

Notes:

1. Based on average exchange rate of ₹83.4 per USD for quarter ended June 30, 2024, ₹83.0 per USD for quarter ended March 31, 2024, and ₹82.2 per USD for quarter ended June 30, 2023, respectively.
2. Based on INR revenue. YoY growth for quarter June 30, 2023, based on unaudited financials.
3. Earnings before interest, taxes, depreciation and amortization ("EBITDA") represents profit/(loss) for the period before income tax expense, finance costs, depreciation and amortization expense, interest income and any exceptional items.

"In Q1FY25, we achieved revenue growth of 11.4% and robust EBITDA growth of 14.5% vs Q1FY24. We continue to see momentum and growth with our largest client and a few of our Top 20 clients with increased activity and volume levels tracking the larger pipeline of impending new product launches", said Manish Gupta, Chairman and CEO, Indegene Limited. "Based on our conversations with our top clients, we anticipate similar momentum across the industry. Further, compared to last year, our pipeline is healthier and the quality of conversations with clients is much better, which gives us confidence about driving robust growth in the medium term."

"Our Q1FY25 EBITDA margin of 19.6% and PAT margin of 13.0% is an improvement of 50 bps and 170 bps vs Q1FY24. Indegene is now a zero-debt company with repayment of loans, and we anticipate the financial leverage to drive stronger PAT growth going forward", said Suhas Prabhu, CFO, Indegene Limited. "Also, we continue to strengthen our technology and automation initiatives, which we believe will have a positive impact on the margin in the future. Further, we anticipate that the EBITDA margin would have a similar trajectory as FY24 with a stronger H2 compared to H1."

About Indegene

Indegene Limited (BSE: 544172, NSE: INDGN) is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech, and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. Indegene brings together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable, and omnichannel experience for patients and physicians. It's what drives Indegene's team and their purpose to enable healthcare organizations to be future-ready. To learn more, please visit www.indegene.com

For Investor Inquiries, please contact: IR@Indegene.com

For media inquiries, please contact:

Yadunandan K V | yadunandan.kv@indegene.com